➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Baxter
Harvard Business School
Dow
Boehringer Ingelheim

Last Updated: September 18, 2021

DrugPatentWatch Database Preview

Concordia Pharms Inc Company Profile


Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for CONCORDIA PHARMS INC, and what generic and branded alternatives to CONCORDIA PHARMS INC drugs are available?

CONCORDIA PHARMS INC has three approved drugs.



Summary for Concordia Pharms Inc
US Patents:0
Tradenames:4
Ingredients:2
NDAs:3

Drugs and US Patents for Concordia Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-001 Jun 1, 2006 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-003 Jun 1, 2006 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial
Concordia Pharms Inc ORAPRED prednisolone sodium phosphate SOLUTION;ORAL 075117-001 Dec 14, 2000 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Concordia Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-001 Jun 1, 2006 6,740,341 ⤷  Free Forever Trial
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 5,178,878 ⤷  Free Forever Trial
Concordia Pharms Inc JENLOGA clonidine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022331-001 Sep 30, 2009 5,869,100 ⤷  Free Forever Trial
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 6,221,392 ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for CONCORDIA PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Orally Disintegrating Tablets 10 mg, 15 mg and 30 mg ➤ Subscribe 2010-07-22
➤ Subscribe Extended-release Tablets 0.1 mg and 0.2 mg ➤ Subscribe 2011-03-04
➤ Subscribe Extended-release Tablets 0.1 mg and 0.2 mg ➤ Subscribe 2011-03-04
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Express Scripts
Baxter
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.